CoChat

Current and emerging concepts for systemic treatment of metastatic colorectal cancer

Open access
Steup, Christoph, Kennel, Kilian B, Neurath, Markus F, Fichtner-Feigl, Stefan, Greten, Florian R · 2025 · Gut

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index; 27 of the 135 sources its claims cite were checked for support.

Abstract

Colorectal cancer (CRC) is one of the most common malignant cancers and its incidence is steadily rising particularly in young patients. While screening measures and the widespread availability of surgical treatment have led to an impressive improvement of prognosis within the overall CRC population, patients with metastatic CRC still face 5-year survival rates of around 10–25%. Despite continuous development of new systemic treatment strategies that include cytotoxic chemotherapy and targeted therapy, most patients with metastatic CRC eventually progress. However, a small proportion of patients with mismatch repair-deficient or microsatellite unstable CRC responds exceptionally well to treatment with immune checkpoint inhibitors, thereby proving that CRC is in principle amenable to immunotherapy and showing that long-term disease stabilisation can be achieved even in metastasised stages. However, the reasons for the lack of response to immunotherapy in the vast majority of CRC cases remain to be elucidated. Yet, recent evidence suggests that the tumour stroma, which includes non-immune cells in the colorectal tumour microenvironment, mediates immunosuppressive mechanisms that prevent effective immunotherapy. These findings open new avenues for the development of advanced immunotherapies for CRC. In this review, we summarise major developments in the systemic therapy of CRC within the last couple of decades, provide an overview of emerging and soon-to-be implemented therapeutic strategies and present concepts from clinical and preclinical research to manipulate tumour cells and the tumour stroma to sensitise microsatellite stable colorectal tumours to immunotherapy.

Overview

CoChat Summary

TL;DR

This review summarizes systemic treatment of metastatic colorectal cancer (mCRC), emphasizing that pMMR/MSS tumors remain largely resistant to immunotherapy while dMMR/MSI-H tumors can achieve durable responses to immune checkpoint blockade (ICB). It highlights emerging biomarker-driven targeted therapies, antibody-drug conjugates, and tumor microenvironment/stroma-directed strategies to sensitize MSS/pMMR mCRC to immunotherapy.

Key findings

  • mCRC prognosis remains poor: 5-year survival is around 10–25%; about 20–25% of CRC cases are metastatic at diagnosis; half of patients with mCRC die within approximately 30 months; global CRC-related deaths are projected to rise from around 915,000 in 2020 to over 1.5 million in 2040. Chemotherapy improved overall survival from approximately 6 months in untreated historical cohorts to 16–20 months for FOLFOX or FOLFIRI, while surgical resection of metastases is feasible in only 10–30% of patients.
  • dMMR/MSI-H CRC, around 3–15% of cases, is highly immunogenic and responds to ICB; a 2015 phase II trial showed durable responses in more than 50% of dMMR/MSI-H patients, and Keynote-177 established pembrolizumab as first-line standard of care. CheckMate 8HW confirmed strong efficacy of dual ipilimumab plus nivolumab, but up to 50% of patients on single-agent ICB and up to 25% on double-agent ICB progress within the first 6 months.
  • pMMR/MSS tumors, approximately 90% of CRC, are immune-cold and do not respond to ICB; the tumor stroma, including cancer-associated fibroblasts, TGF-β, immune exclusion, and MHC-I loss, mediates immunosuppression. TME-based biomarkers such as the immunoscore and IS-IC may select responders; in the FFCD 1703-POCHI trial, preliminary 10-month PFS was almost 70% in patients with high tumorous leucocyte infiltration.
  • Emerging targeted and antibody-drug conjugate data include KRAS p.G12C in approximately 3% of CRC, with sotorasib plus panitumumab showing median PFS of 5.6 vs 2.2 months, and adagrasib plus cetuximab showing ORR 34%, DCR 85.1%, mPFS 6.9 months, and mOS 15.9 months. ERBB2 amplification is about 3% overall and 5–7% in left-sided RAS/BRAF wild-type tumors; MOUNTAINEER reported tucatinib plus trastuzumab ORR 38.1%, mPFS 8.2 months, and mOS 24.1 months, while DESTINY-CRC02 reported T-DXd ORR 37.8% at 5.4 mg/kg and 27.5% at 6.4 mg/kg.

Methods

  • Narrative review of clinical and preclinical literature on systemic therapy for mCRC, covering current standard of care, emerging biomarker-driven therapies, ICB, antibody-drug conjugates, bispecific antibodies, and TME/stroma-targeted strategies.
  • Synthesizes published trial results and ongoing clinical trials, with tables listing NCT numbers, phases, patient populations, biomarker stratification, treatments, and outcomes.
  • No systematic review methodology, search strategy, or meta-analysis is reported.

Limitations

  • Stated: treatment standards are region- and country-specific; survival data in Figure 1 derive from selected trial-eligible patients and should not be used for general population prediction; trials mostly include CRC liver metastasis and underrepresent peritoneal metastasis.
  • Stated: clinical translation of TGF-β inhibition plus immunotherapy has largely failed despite preclinical promise; IS-IC needs further validation in different cohorts; CAR-T and adoptive cell therapies have so far been unsuccessful in solid malignancies like CRC.
  • Evident: as a narrative review, it lacks a formal systematic search and quality appraisal and relies on selected literature and ongoing trial registrations; many cited emerging approaches are early-phase or ongoing without mature overall survival data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2025-335412

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Metastatic colorectal cancer therapy evolution. Median overall survival for systemic treatment and in regard to surgical resection is based on Zeineddine, FA, Zeineddine, MA, Yousef, A et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis. Onc. 7, 16 (2023). The median response and survival times reported for the sequential treatment options are based on prototypical patients who are willing to undergo intensive treatment and who are fit and healthy enough. If patients are unable or unwilling to receive the proposed intensive treatment, further treatment should be determined through a process of shared decision-making with the patient. Whenever treatment is ended, further therapy should be symptom-driven in the form of best supportive care. Treatment durations are estimated based on progression-free survival in the relevant trials indicated or discussed in the text. There is a large interindividual variation in progression-free survival, and therefore the actual duration of treatment may be shorter for patients with progressive disease and longer for those with stable disease based on tumour biology. Some patients may even undergo treatment breaks, which are not shown for graphical illustration purposes. Further, for the MSI-high/dMMR subgroup, the overall survival data are not available yet and therefore the response times for further treatment lines can only be estimated, and some patients will not need further treatment due to a complete response. In addition, experimental therapies in clinical trials should be considered at any new treatment point. The figure is not intended to be used as a treatment algorithm and local guidelines should always be used for clinical decision-making and local drug approval status must be considered. BRAF, v-Raf murine sarcoma viral oncogene homolog B; CLMR, colorectal cancer liver metastasis resection; CRC, colorectal cancer; dMMR, mismatch repair deficiency; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; FDA, Food and Drug Administration; FOLFOX, doublet chemotherapy regimen with intravenous fluorouracil/leucovorin and oxaliplatin; FOLFIRI, doublet chemotherapy regimen with intravenous fluorouracil/leucovorin and irinotecan; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; mCRC, metastatic CRC; mOS, median OS; MSI, microsatellite instability; MSS, microsatellite stable; OS, overall survival; pMMR, mismatch repair proficient; RAS, rat sarcoma; TS-1/S-1, tegafur/gimeracil/oteracil; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; WT, wild type.
Figure 1 Metastatic colorectal cancer therapy evolution. Median overall survival for systemic treatment and in regard to surgical resection is based on Zeineddine, FA, Zeineddine, MA, Yousef, A et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis. Onc. 7, 16 (2023). The median response and survival times reported for the sequential treatment options are based on prototypical patients who are willing to undergo intensive treatment and who are fit and healthy enough. If patients are unable or unwilling to receive the proposed intensive treatment, further treatment should be determined through a process of shared decision-making with the patient. Whenever treatment is ended, further therapy should be symptom-driven in the form of best supportive care. Treatment durations are estimated based on progression-free survival in the relevant trials indicated or discussed in the text. There is a large interindividual variation in progression-free survival, and therefore the actual duration of treatment may be shorter for patients with progressive disease and longer for those with stable disease based on tumour biology. Some patients may even undergo treatment breaks, which are not shown for graphical illustration purposes. Further, for the MSI-high/dMMR subgroup, the overall survival data are not available yet and therefore the response times for further treatment lines can only be estimated, and some patients will not need further treatment due to a complete response. In addition, experimental therapies in clinical trials should be considered at any new treatment point. The figure is not intended to be used as a treatment algorithm and local guidelines should always be used for clinical decision-making and local drug approval status must be considered. BRAF, v-Raf murine sarcoma viral oncogene homolog B; CLMR, colorectal cancer liver metastasis resection; CRC, colorectal cancer; dMMR, mismatch repair deficiency; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; FDA, Food and Drug Administration; FOLFOX, doublet chemotherapy regimen with intravenous fluorouracil/leucovorin and oxaliplatin; FOLFIRI, doublet chemotherapy regimen with intravenous fluorouracil/leucovorin and irinotecan; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma; mCRC, metastatic CRC; mOS, median OS; MSI, microsatellite instability; MSS, microsatellite stable; OS, overall survival; pMMR, mismatch repair proficient; RAS, rat sarcoma; TS-1/S-1, tegafur/gimeracil/oteracil; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; WT, wild type.CC BY-NC · PubMed Central
Figure 2 Prototypical immune subtypes of CRC and stromal mechanisms of resistance towards immunotherapy. (A) Immune-inflamed CRCs are usually MSI-H, belong to the CMS1, have a high immunoscore and respond to immune checkpoint blockade. Due to the high neo-antigen load, MSI-H CRCs recruit antigen-specific CD8+ T cells which kill cancer cells and keep the tumour in check. In these highly inflamed tumours, stromal fibroblasts seem to acquire an inflammatory phenotype (Pelka et al, Cell 2021) whose functional implications are largely unknown. Immune checkpoints such as PD-1/PD-L1 are amply present, inhibit tumour cell killing by CD8+ T cells and can be overcome using ICB. (B) In immune-excluded, deserted or ‘pseudo’-hot CRCs, which are mostly MSS and of the CMS2, 3 or 4, antigen-specific CD8+ T cells are scarce due to low neoantigen load. In addition, antigen-specific CD8+ T cells are inhibited by immunosuppressive myeloid cells or excluded from the TME by fibroblasts that acquire a myofibroblastic phenotype through activation by TGF-β. Infiltration of tumours with unspecific, naïve T cells and other immune cells might generate the picture of a ‘pseudo’-hot tumour that does not respond to immune interventions. (C) Increasing neoantigenicity of MSS CRCs is likely a prerequisite for successful immunotherapies of MSS CRC. However, stromal fibroblasts subvert the actions of, for example, tumour vaccines, oncolytic viruses and conventional genotoxic and targeted therapies by various means: TGF-β-activated myofibroblasts generate ROS, TGF-β and IL-6 to exclude T cells from the TME, polarise them towards non-effector phenotypes and downregulate MHC I on tumour cells which limits all types of antigen-dependent immunity and torpedoes strategies to extrinsically deliver antigens such as neo-antigen vaccination. Furthermore, fibroblasts inhibit the cytotoxicity of both conventional (chemo, radio and targeted) and oncolytic viral therapies through YAP, TGF-β, HGF, FGFs and type I IFNs. As these therapies can result in the generation and/or release of antigens into the TME, stromal fibroblasts thereby indirectly reduce tumour antigenicity. Reduction of the immunosuppressive traits of myofibroblasts by inhibition of TGF-β and concomitant pro-inflammatory stimulation of stromal fibroblasts together with the augmentation of tumour antigenicity might represent a combinatorial strategy to enable adaptive immune control of MSS CRC. Blockade of IL-1a induced CAF polarisation can prevent therapy induced senescence in rectal cancer. CAF, cancer-associated fibroblast; CD8, cluster of differentiation 8; CMS, consensus molecular subtype; CRC, colorectal cancer; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; ICB, immune checkpoint blockade; IL-6, interleukin 6; IFN, interferon; MHC I, major histocompatibility complex I; mRNA, messenger RNA; MSI-H, microsatellite instability high; MSS, microsatellite stable; PD-1/PD-L1, programmed cell death protein 1/ligand 1; ROS, reactive oxygen species; TGF-β, transforming growth factor-beta; TME, tumour microenvironment; YAP, Yes-associated protein.
Figure 2 Prototypical immune subtypes of CRC and stromal mechanisms of resistance towards immunotherapy. (A) Immune-inflamed CRCs are usually MSI-H, belong to the CMS1, have a high immunoscore and respond to immune checkpoint blockade. Due to the high neo-antigen load, MSI-H CRCs recruit antigen-specific CD8+ T cells which kill cancer cells and keep the tumour in check. In these highly inflamed tumours, stromal fibroblasts seem to acquire an inflammatory phenotype (Pelka et al, Cell 2021) whose functional implications are largely unknown. Immune checkpoints such as PD-1/PD-L1 are amply present, inhibit tumour cell killing by CD8+ T cells and can be overcome using ICB. (B) In immune-excluded, deserted or ‘pseudo’-hot CRCs, which are mostly MSS and of the CMS2, 3 or 4, antigen-specific CD8+ T cells are scarce due to low neoantigen load. In addition, antigen-specific CD8+ T cells are inhibited by immunosuppressive myeloid cells or excluded from the TME by fibroblasts that acquire a myofibroblastic phenotype through activation by TGF-β. Infiltration of tumours with unspecific, naïve T cells and other immune cells might generate the picture of a ‘pseudo’-hot tumour that does not respond to immune interventions. (C) Increasing neoantigenicity of MSS CRCs is likely a prerequisite for successful immunotherapies of MSS CRC. However, stromal fibroblasts subvert the actions of, for example, tumour vaccines, oncolytic viruses and conventional genotoxic and targeted therapies by various means: TGF-β-activated myofibroblasts generate ROS, TGF-β and IL-6 to exclude T cells from the TME, polarise them towards non-effector phenotypes and downregulate MHC I on tumour cells which limits all types of antigen-dependent immunity and torpedoes strategies to extrinsically deliver antigens such as neo-antigen vaccination. Furthermore, fibroblasts inhibit the cytotoxicity of both conventional (chemo, radio and targeted) and oncolytic viral therapies through YAP, TGF-β, HGF, FGFs and type I IFNs. As these therapies can result in the generation and/or release of antigens into the TME, stromal fibroblasts thereby indirectly reduce tumour antigenicity. Reduction of the immunosuppressive traits of myofibroblasts by inhibition of TGF-β and concomitant pro-inflammatory stimulation of stromal fibroblasts together with the augmentation of tumour antigenicity might represent a combinatorial strategy to enable adaptive immune control of MSS CRC. Blockade of IL-1a induced CAF polarisation can prevent therapy induced senescence in rectal cancer. CAF, cancer-associated fibroblast; CD8, cluster of differentiation 8; CMS, consensus molecular subtype; CRC, colorectal cancer; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; ICB, immune checkpoint blockade; IL-6, interleukin 6; IFN, interferon; MHC I, major histocompatibility complex I; mRNA, messenger RNA; MSI-H, microsatellite instability high; MSS, microsatellite stable; PD-1/PD-L1, programmed cell death protein 1/ligand 1; ROS, reactive oxygen species; TGF-β, transforming growth factor-beta; TME, tumour microenvironment; YAP, Yes-associated protein.CC BY-NC · PubMed Central

Verification

Claims the paper makes

19 Valid · 3 Not valid · 92 Not checked · 16 Own results and interpretations

64 more claims · 5 with their cited sources checked

Create a free account to see all 130 claims and to verify the 108 references still open.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 53

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 168 references

Research works printed but not linked: 3

  1. 10.1002/1097-0142(19900501)65:9&2091::aid-cncr2820650934 · doi:10.1002/1097-0142(19900501)65:9&2091::aid-cncr2820650934
  2. Alese, 2023, Update on Emerging Therapies for Advanced Colorectal Cancer, Am Soc Clin Oncol Educ Book, 43, 10.1200/edbk_389574 · DOI
  3. 10.1200/jco.22.01690 · DOI · Paper page

Cited by

See all 45

Metadata

Authors
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R.
Affiliations
  • Goethe University Frankfurt (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
Corresponding author
Greten, Florian R
Venue
Gut
Publisher
BMJ
Published
2025-10-05
Volume
74
Issue
12
Pages
2070-2095
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4414833677
Cited by
39
References
167
Citations by year
2026: 34 · 2025: 5
FWCI
4.58
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
Funders
H2020 European Research Council (101021078)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
metastatic colorectal cancer, systemic therapy, immunotherapy, immune checkpoint inhibitors, mismatch repair deficiency, microsatellite instability, tumor microenvironment, tumor stroma, immunosuppression, chemotherapy, targeted therapy, immunotherapy resistance
MeSH terms
Immune Checkpoint Inhibitors, Humans, Immunotherapy, Neoplasm Metastasis, Colorectal Neoplasms, Microsatellite Instability, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current and emerging concepts for systemic treatment of metastatic colorectal cancer. https://app.cochat.ai/papers/10.1136/gutjnl-2025-335412
The paper
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025). Current and emerging concepts for systemic treatment of metastatic colorectal cancer. Gut. https://doi.org/10.1136/gutjnl-2025-335412

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.